J.P. Morgan Roundtable: Financing Challenges, And Opportunities, For Complex Therapies
Part 1: Scrip spoke with companies working on cell and gene therapies and novel neuroscience platforms – areas difficult to finance in the past, but seeing increasing investor interest – about funding challenges and opportunities in 2019.
You may also be interested in...
Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.
An all-stock transaction will see Europe’s Kiadis and US’s CytoSen bring together complementary approaches to improving stem cell transplants and cancer immunotherapy.
It's early days yet and Alzheimer's is a field littered with failures, but the latest results for the vaccine UB-311 support advancing development.